Poxel has raised €13m ($17m) in a series B round financing to develop and confirm efficacy data of Imeglimin, a drug used to treat type 2 diabetes. Imeglimin is a new tetrahydrotriazine-containing class of oral anti- diabetics, the ...
Tags: Poxel, efficacy data of Imeglimin, drug, ype 2 diabetes